Annexin Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Annexin Pharmaceuticals
Access all reports
Annexin Pharmaceuticals AB is a Swedish biotechnology company focused on developing innovative therapies for cardiovascular and inflammatory diseases. Its lead product, ANXV, is a recombinant human protein, Annexin A5, which has the potential to treat conditions related to blood vessel damage and inflammation. The drug is currently undergoing clinical trials, particularly for Retinal Vein Occlusion (RVO), a condition that can lead to vision loss, and shows potential for broader applications, including in oncology. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
Ticker symbol
ANNX
Country
🇸🇪 Sweden